Free Cash Flow (Quarterly) Chart

View Free Cash Flow (Quarterly) for RXRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow (Quarterly) Chart
Start Trial

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 -107.91M
March 31, 2026 -81.44M
December 31, 2025 -47.32M
September 30, 2025 -117.60M
June 30, 2025 -81.73M
March 31, 2025 -133.79M
December 31, 2024 -117.08M
September 30, 2024 -63.79M
June 30, 2024 -86.40M
March 31, 2024 -108.95M
December 31, 2023 -76.49M
September 30, 2023 -73.75M
June 30, 2023 -71.44M
Date Value
March 31, 2023 -78.66M
December 31, 2022 -52.73M
September 30, 2022 -63.10M
June 30, 2022 -78.10M
March 31, 2022 73.05M
December 31, 2021 -65.62M
September 30, 2021 -42.75M
June 30, 2021 -39.86M
March 31, 2021 -50.17M
December 31, 2020 3.982M
September 30, 2020 -20.28M
June 30, 2020 -17.33M
March 31, 2020 -18.50M

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
Twist Bioscience Corp. -8.648M
Absci Corp. -27.56M
Novavax, Inc. -73.40M
Editas Medicine, Inc. -29.67M
Halozyme Therapeutics, Inc. 236.72M